Overview
- Novo Nordisk is now selling Wegovy to cash-paying patients for $349 per month, with most Ozempic doses at the same price except the 2 mg dose at $499.
- An introductory $199 monthly offer covers the lowest two doses of Wegovy and Ozempic for two months for new cash patients through March 31, 2026.
- Eli Lilly plans to price the lowest Zepbound dose at $299 per month starting in January, with higher doses at $449 for cash payers under the new arrangement.
- Under the White House agreements, injectable obesity drugs are slated to cost Medicare and Medicaid $245 per month net, with $149 starter doses available via TrumpRx for eligible users and cash buyers.
- GoodRx will launch a Wegovy and Ozempic telehealth service at $39 per month for sign-ups before February 1, 2026, rising to $119 afterward, compared with list prices of about $1,349 for Wegovy and over $1,250 for Zepbound.